Loading...

Stephen Gitelman, MD

Title(s)Professor, Pediatrics
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-476-1016
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPost-Doc Fellow/Scholar1990 Medicine (Pediatrics)
    University of California, San Francisco Residency School of Medicine
    University of North CarolinaM.D.1984School of Medicine

    Collapse Overview 
    Collapse Overview
    I am involved in a variety of different translational and clinical research projects, most related to diabetes. A number of the on-going studies are attempts to alter the course of autoimmune-mediated type 1 diabetes, often via immunomodulation, in order to preserve endogenous beta cell function. Some of the recent and on-going projects are described below.

    Most of this work occurs in multi-center clinical trials. I am the Clinical Center director for the NIH sponsored program TrialNet, a multi-center research consortium that develops trials to delay or prevent the onset of type 1 diabetes in those at risk, or prolong endogenous insulin secretion (the honeymoon phase) in those with new onset disease. UCSF is one of 14 national centers for this 7-year study. Current studies include:
    -natural history study to screen and predict who might develop type 1 diabetes
    -a prevention trial with omega 3 fatty acids to determine if treatment during pregnancy or shortly after birth can serve as a primary means to prevent type 1 diabetes
    -a new onset diabetes trial with mycophenolate mofetil with our without IL-2 receptor monoclonal antibody to determine if this will preserve endogenous insulin secretion
    -a new onset study with anti-CD20 monoclonal antibody to determine if this will preserve endogenous insulin secretion
    The consortium is continuing to develop additional prevention and new onset studies over time.

    In addition, I have served as the site director for a novel study evaluating the role of an anti-CD3 monoclonal antibody in prolonging the honeymoon phase in those with new onset type 1 diabetes. The initial phase 1 / 2 study results were published in the N Engl J Med 2002, and our 2 year follow-up data was just published (Diabetes 2005). These exciting results were confirmed in an independent study with a related drug in Europe, and have spawned a series of studies to build on these initial findings. We are now launching an NIH-sponsored phase 2 study for new onset diabetes, evaluating the efficacy of antibody treatment every 12 months for 2 courses. In addition to these efforts, we have several additional NIH-funded new onset type 1 diabetes studies that will soon begin. We are evaluating the window of opportunity for anti-CD3 therapy, with a trial planned for subjects from 4 to 12 months from diagnosis. We are developing clinical trials the assess the effect of anti-CD3 therapy coupled with antigen, and another study coupling with an incretin hormone analgoue, exenatide, which may help with beta cell regeneration. Finally, I am the study principal investigator for a multi-center new onset type 1 diabetes trial with anti-thymocyte globulin, sponsored by the Immune Tolerance Network.

    I am partnering with other members of the UCSF Diabetes Center to pursue other clinical trials, and translational studies that may help us better understand the pathogenesis of type 1 diabetes. Such studies include development of T cell assays; characterization of patients with novel disorders in carbohydrate metabolism; possible use of T regulatory cells as an immunotherapy. As technology advances, we anticipate to one day be able to use beta cells developed from stem cells as a definitive treatment for type 1 diabetes.

    Collapse Research 
    Collapse Research Activities and Funding
    K12 In Diabetes (KIDS)
    NIH/NIDDK K12DK094726Sep 16, 2011 - Jul 31, 2016
    Role: Principal Investigator
    Continuation of UCSF as a Clinical Center for TrialNet
    NIH/NIDDK U01DK061010Sep 29, 2001 - Sep 30, 2008
    Role: Principal Investigator
    VGR-1/BMP-6 AND CHONDROGENESIS AND OSTEOGENESIS
    NIH/NIAMS K08AR001897Apr 1, 1993 - Mar 31, 1998
    Role: Principal Investigator
    TRANSCRIPTIONAL REGULATION OF P450 C17 GENE
    NIH/NIDDK F32DK008325Sep 1, 1989
    Role: Principal Investigator
    PEDIATRIC CLINICAL RESEARCH CENTER
    NIH/NCRR M01RR001271Dec 1, 1981 - Sep 29, 2006
    Role: Co-Investigator
    Training Program in Pediatric Endocrinology
    NIH/NIDDK T32DK007161Jul 1, 1976 - Jun 30, 2021
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Exenatide ER in patients with Type 1 diabetes with and without residual insulin production. Diabetes Obes Metab. 2020 Jun 23. Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop-Busui R, Weinstock RS. PMID: 32573927.
      View in: PubMed   Mentions:    Fields:    
    2. Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia. 2020 04; 63(4):885-886. Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC. PMID: 31982961.
      View in: PubMed   Mentions:    Fields:    
    3. Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. Diabetes Care. 2020 Mar; 43(3):580-587. Ferrara-Cook C, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Gitelman SE, Redondo MJ. PMID: 31937610.
      View in: PubMed   Mentions:    Fields:    
    4. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI Insight. 2019 12 19; 4(24). Herold KC, Bucktrout SL, Wang X, Bode BW, Gitelman SE, Gottlieb PA, Hughes J, Joh T, McGill JB, Pettus JH, Potluri S, Schatz D, Shannon M, Udata C, Wong G, Levisetti M, Ganguly BJ, Garzone PD. PMID: 31852846.
      View in: PubMed   Mentions:    Fields:    
    5. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care. 2020 Jan; 43(1):5-12. Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M. PMID: 31753960.
      View in: PubMed   Mentions: 3     Fields:    
    6. Elicited and pre-existing anti-Neu5Gc antibodies differentially affect human endothelial cells transcriptome. Xenotransplantation. 2019 11; 26(6):e12535. Le Berre L, Danger R, Mai HL, Amon R, Leviatan Ben-Arye S, Bruneau S, Senage T, Perreault H, Teraiya M, Nguyen TVH, Le Tourneau T, Yu H, Chen X, Galli C, Roussel JC, Manez R, Costa C, Brouard S, Galinanes M, Harris KM, Gitelman S, Cozzi E, Charreau B, Padler-Karavani V, Soulillou JP. PMID: 31293002.
      View in: PubMed   Mentions: 3     Fields:    
    7. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 08 15; 381(7):603-613. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ. PMID: 31180194.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    8. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes. 2019 06; 68(6):1267-1276. Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ. PMID: 30967424.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    9. Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables. Diabetologia. 2019 01; 62(1):33-40. Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC. PMID: 30167735.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    10. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ß-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care. 2018 Sep; 41(9):1917-1925. Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ. PMID: 30012675.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    11. Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy. Oncotarget. 2017 Dec 22; 8(68):112236-112244. Amon R, Ben-Arye SL, Engler L, Yu H, Lim N, Berre LL, Harris KM, Ehlers MR, Gitelman SE, Chen X, Soulillou JP, Padler-Karavani V. PMID: 29348821.
      View in: PubMed   Mentions: 8     Fields:    
    12. The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. J Clin Endocrinol Metab. 2017 12 01; 102(12):4596-4603. Ferrara CT, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Wentworth JM, Moran A, Gitelman SE, Redondo MJ. PMID: 29092051.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    13. A new familial form of a late-onset, persistent hyperinsulinemic hypoglycemia of infancy caused by a novel mutation in KCNJ11. Channels (Austin). 2017 Nov 02; 11(6):636-647. Yang YY, Long RK, Ferrara CT, Gitelman SE, German MS, Yang SB. PMID: 29087246.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    14. Type 1 Diabetes and Celiac Disease: Causal Association or True, True, Unrelated? Pediatrics. 2017 11; 140(5). Ferrara CT, Gitelman SE. PMID: 29018047.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs. Transplantation. 2017 10; 101(10):2501-2507. Salama A, Evanno G, Lim N, Rousse J, Le Berre L, Nicot A, Bach JM, Brouard S, Harris KM, Ehlers MR, Gitelman SE, Soulillou JP. PMID: 28198767.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCTClinical Trials
    16. Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? Diabetes Care. 2017 05; 40(5):698-701. Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ, Rodriguez H, Moran A, Gitelman SE, Redondo MJ. PMID: 28202550.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    17. Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. Diabetes Care. 2016 Dec; 39(12):2218-2224. Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY. PMID: 27872156.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. Diabetes. 2016 Dec; 65(12):3765-3775. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA. PMID: 27669730.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    19. Regulatory T cell therapy for type 1 diabetes: May the force be with you. J Autoimmun. 2016 07; 71:78-87. Gitelman SE, Bluestone JA. PMID: 27133597.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    20. Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes. Diabetes Care. 2016 06; 39(6):e76-8. Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC. PMID: 27208317.
      View in: PubMed   Mentions: 1     Fields:    
    21. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. 2016 06; 59(6):1153-61. Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR. PMID: 27053235.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    22. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25; 7(315):315ra189. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. PMID: 26606968.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansCellsCTClinical Trials
    23. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015 Oct; 38(10):1975-85. Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ. PMID: 26404927.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    24. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 03; 125(8):3285-96. Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. PMID: 26193635.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCellsCTClinical Trials
    25. Anti-thymocyte globulin/G-CSF treatment preserves ß cell function in patients with established type 1 diabetes. J Clin Invest. 2015 Jan; 125(1):448-55. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA. PMID: 25500887.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCellsCTClinical Trials
    26. Recommendations for the definition of clinical responder in insulin preservation studies. Diabetes. 2014 Sep; 63(9):3120-7. Beam CA, Gitelman SE, Palmer JP. PMID: 24722251.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    27. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014 Apr; 37(4):1069-75. Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS. PMID: 24296850.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    28. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):284-94. Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR. PMID: 24622414.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCellsCTClinical Trials
    29. B-lymphocyte depletion with rituximab and ß-cell function: two-year results. Diabetes Care. 2014 Feb; 37(2):453-9. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS. PMID: 24026563.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCellsCTClinical Trials
    30. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):306-16. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR. PMID: 24622416.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    31. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 62(11):3766-74. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA. PMID: 23835333.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    32. Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr Diabetes. 2013 Aug; 14(5):311-21. Thomas HR, Gitelman SE. PMID: 23773203.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    33. Combined pancreatic islet and kidney transplantation in a child with unstable type 1 diabetes and end-stage renal disease. Am J Transplant. 2013 Aug; 13(8):2207-10. Benedict KA, Moassesfar S, Adi S, Gitelman SE, Brennan JL, McEnhill M, Stock PG, Portale AA, Posselt AM. PMID: 23763601.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Comparison of autoantibody-positive and autoantibody-negative pediatric participants enrolled in the T1D Exchange clinic registry. J Diabetes. 2013 Jun; 5(2):216-23. Gerard-Gonzalez A, Gitelman SE, Cheng P, Dubose SN, Miller KM, Olson BA, Redondo MJ, Steck AK, Beck RW. PMID: 23368514.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013 Jun 01; 381(9881):1905-15. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T. PMID: 23562090.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCells
    36. A cross-sectional study of osteocalcin and body fat measures among obese adolescents. Obesity (Silver Spring). 2013 Apr; 21(4):808-14. Lenders CM, Lee PD, Feldman HA, Wilson DM, Abrams SH, Gitelman SE, Klish WJ, Wertz MS, Taylor GA, Alongi RT, Chen TC, Holick MF. PMID: 23712984.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    37. Immune therapy and ß-cell death in type 1 diabetes. Diabetes. 2013 May; 62(5):1676-80. Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC. PMID: 23423576.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    38. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013 Feb; 56(2):391-400. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. PMID: 23086558.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    39. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012 Aug; 61(8):2066-73. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM. PMID: 22688329.
      View in: PubMed   Mentions: 100     Fields:    Translation:HumansCells
    40. Persistent elevation of urine aquaporin-2 during water loading in a child with nephrogenic syndrome of inappropriate antidiuresis (NSIAD) caused by a R137L mutation in the V2 vasopressin receptor. Int J Pediatr Endocrinol. 2012 Feb 10; 2012(1):3. Cheung CC, Cadnapaphornchai MA, Ranadive SA, Gitelman SE, Rosenthal SM. PMID: 22325688.
      View in: PubMed   Mentions:
    41. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Jul 30; 378(9789):412-9. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS. PMID: 21719096.
      View in: PubMed   Mentions: 185     Fields:    Translation:HumansCellsCTClinical Trials
    42. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011 Jul 23; 378(9788):319-27. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS. PMID: 21714999.
      View in: PubMed   Mentions: 115     Fields:    Translation:Humans
    43. Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population? Pediatr Diabetes. 2011 Jun; 12(4 Pt 2):442-59. Glaser NS, Geller DH, Haqq A, Gitelman S, Malloy M. PMID: 21054719.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Impact of an interactive online nursing educational module on insulin errors in hospitalized pediatric patients. Diabetes Care. 2010 Aug; 33(8):1744-6. Sullivan MM, O'Brien CR, Gitelman SE, Shapiro SE, Rushakoff RJ. PMID: 20504898.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    45. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol. 2010 May; 77(5):836-45. Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M. PMID: 20159941.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    46. Long-term outcomes in a family with nephrogenic syndrome of inappropriate antidiuresis. Int J Pediatr Endocrinol. 2009; 2009:431527. Cho YH, Gitelman S, Rosenthal S, Ambler G. PMID: 20148077.
      View in: PubMed   Mentions:
    47. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009 Nov 26; 361(22):2143-52. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS. PMID: 19940299.
      View in: PubMed   Mentions: 321     Fields:    Translation:HumansCells
    48. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009 Aug 12; 302(6):624; author reply 624-5. Gitelman SE, Haller MJ, Schatz D. PMID: 19671901.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    49. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am J Clin Nutr. 2009 Sep; 90(3):459-67. Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, Wilson DM, Lee PD, Abrams SH, Gitelman SE, Wertz MS, Klish WJ, Taylor GA, Chen TC, Holick MF. PMID: 19640956.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    50. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug; 132(2):166-73. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA. PMID: 19443276.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    51. The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2008 Jun; 9(3 Pt 2):69-73. Huang EA, Gitelman SE. PMID: 18221433.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Congenital hyperinsulinism in an infant caused by a macroscopic insulin-producing lesion. J Pediatr Endocrinol Metab. 2007 Mar; 20(3):437-40. Bremer AA, Nobuhara KK, Gitelman SE. PMID: 17451083.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction. Pediatr Endocrinol Rev. 2006 Dec; 4 Suppl 1:66-70. Rosenthal SM, Feldman BJ, Vargas GA, Gitelman SE. PMID: 17261972.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006 Sep; 55(9):2588-94. Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC. PMID: 16936208.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    55. Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients. Am J Med. 2006 Jul; 119(7 Suppl 1):S54-8. Gitelman SE, Feldman BJ, Rosenthal SM. PMID: 16843086.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    56. Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children. J Pediatr. 2006 Jan; 148(1):128-31. Huang EA, Feldman BJ, Schwartz ID, Geller DH, Rosenthal SM, Gitelman SE. PMID: 16423613.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    57. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab. 2005 Sep; 18(9):865-72. Sapru A, Gitelman SE, Bhatia S, Dubin RF, Newman TB, Flori H. PMID: 16279364.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    58. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun; 54(6):1763-9. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. PMID: 15919798.
      View in: PubMed   Mentions: 208     Fields:    Translation:HumansCTClinical Trials
    59. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005 May 05; 352(18):1884-90. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE. PMID: 15872203.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    60. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005 Jan; 28(1):15-9. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. PMID: 15616227.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    61. The use of a continuous glucose monitoring system in hypoglycemic disorders. J Pediatr Endocrinol Metab. 2004 Mar; 17(3):281-8. Conrad SC, Mastrototaro JJ, Gitelman SE. PMID: 15112904.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    62. Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb; 53(2):426-33. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. PMID: 14747294.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    63. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30; 346(22):1692-8. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. PMID: 12037148.
      View in: PubMed   Mentions: 361     Fields:    Translation:HumansCTClinical Trials
    64. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr. 2002 Feb; 140(2):235-40. Conrad SC, McGrath MT, Gitelman SE. PMID: 11865277.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    65. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol. 2002 Jan; 17(1):1-5. Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS. PMID: 11793126.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    66. Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients. Diabetologia. 2000 May; 43(5):598-608. Roll U, Turck CW, Gitelman SE, Rosenthal SM, Nolte MS, Masharani U, Ziegler AG, Baekkeskov S. PMID: 10855535.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    67. Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development. 1999 Oct; 126(19):4267-79. Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R. PMID: 10477295.
      View in: PubMed   Mentions: 62     Fields:    Translation:AnimalsCells
    68. Smooth muscle expresses bone morphogenetic protein (Vgr-1/BMP-6) in human fetal intestine. Biol Neonate. 1999 Mar; 75(3):210-4. Perr HA, Ye J, Gitelman SE. PMID: 9925908.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    69. Neonatal hyperinsulinism. Clin Perinatol. 1998 Dec; 25(4):1015-38, viii. Schwitzgebel VM, Gitelman SE. PMID: 9891627.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 1997 Oct; 82(10):3196-202. Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, Wilson CB, Gitelman SE. PMID: 9329338.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    71. Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents. J Clin Endocrinol Metab. 1997 May; 82(5):1362-7. Mootha SL, Barkovich AJ, Grumbach MM, Edwards MS, Gitelman SE, Kaplan SL, Conte FA. PMID: 9141516.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    72. Structure and sequence of the mouse Bmp6 gene. Mamm Genome. 1997 Mar; 8(3):212-4. Gitelman SE, Kobrin M, Lee A, Fet V, Lyons K, Hogan BL, Derynck R. PMID: 9069123.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    73. Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. J Pediatr. 1996 Dec; 129(6):918-21. Silverman LA, Gitelman SE. PMID: 8969738.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    74. A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element? Hum Mol Genet. 1995 Nov; 4(11):2109-16. Tee MK, Babalola GO, Aza-Blanc P, Speek M, Gitelman SE, Miller WL. PMID: 8589688.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    75. Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells. Cell Growth Differ. 1995 Jul; 6(7):827-36. Gitelman SE, Kirk M, Ye JQ, Filvaroff EH, Kahn AJ, Derynck R. PMID: 7547504.
      View in: PubMed   Mentions: 10     Fields:    Translation:Cells
    76. Toward a molecular understanding of skeletal development. Cell. 1995 Feb 10; 80(3):371-8. Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R. PMID: 7859279.
      View in: PubMed   Mentions: 105     Fields:    Translation:HumansAnimals
    77. Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone formation in vivo. J Cell Biol. 1994 Sep; 126(6):1595-609. Gitelman SE, Kobrin MS, Ye JQ, Lopez AR, Lee A, Derynck R. PMID: 8089189.
      View in: PubMed   Mentions: 22     Fields:    Translation:AnimalsCells
    78. Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol. 1993 Jul; 122(1):265-78. Bristow J, Tee MK, Gitelman SE, Mellon SH, Miller WL. PMID: 7686164.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    79. Abundant adrenal-specific transcription of the human P450c21A "pseudogene". J Biol Chem. 1993 Jun 15; 268(17):12919-24. Bristow J, Gitelman SE, Tee MK, Staels B, Miller WL. PMID: 7685353.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    80. Mental retardation locus in Xp21 chromosome microdeletion. Am J Med Genet. 1993 Jun 01; 46(4):363-8. Fries MH, Lebo RV, Schonberg SA, Golabi M, Seltzer WK, Gitelman SE, Golbus MS. PMID: 8357005.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    81. Congenital lipoid adrenal hyperplasia--genes for P450scc, side chain cleavage enzyme, are normal. J Steroid Biochem Mol Biol. 1993 Apr; 45(1-3):87-97. Saenger P, Lin D, Gitelman SE, Miller WL. PMID: 8481356.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    82. Analysis of the duplicated human C4/P450c21/X gene cluster. J Steroid Biochem Mol Biol. 1992 Dec; 43(8):961-71. Miller WL, Gitelman SE, Bristow J, Morel Y. PMID: 22217841.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    83. Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus. Mol Cell Biol. 1992 Jul; 12(7):3313-4. Gitelman SE, Bristow J, Miller WL. PMID: 1620134.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    84. Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus. Mol Cell Biol. 1992 May; 12(5):2124-34. Gitelman SE, Bristow J, Miller WL. PMID: 1373808.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    85. Normal genes for the cholesterol side chain cleavage enzyme, P450scc, in congenital lipoid adrenal hyperplasia. J Clin Invest. 1991 Dec; 88(6):1955-62. Lin D, Gitelman SE, Saenger P, Miller WL. PMID: 1661294.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    86. Cloning of the LH/CG receptor: implications for a unique G-protein coupled receptor. Trends Endocrinol Metab. 1990 Mar-Apr; 1(4):181-4. Gitelman SE. PMID: 18411115.
      View in: PubMed   Mentions:    Fields:    
    87. Transcript encoded on the opposite strand of the human steroid 21-hydroxylase/complement component C4 gene locus. Proc Natl Acad Sci U S A. 1989 Sep; 86(17):6582-6. Morel Y, Bristow J, Gitelman SE, Miller WL. PMID: 2475872.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    88. Purification of calmodulin from Chlamydomonas: calmodulin occurs in cell bodies and flagella. J Cell Biol. 1980 Dec; 87(3 Pt 1):764-70. Gitelman SE, Witman GB. PMID: 6257728.
      View in: PubMed   Mentions: 31     Fields:    Translation:AnimalsCells
    Stephen's Networks
    Concepts (417)
    Derived automatically from this person's publications.
    _
    Co-Authors (38)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _